Basic Information
Leflunomide ratiopharm
Regulatory Information
EMEA/H/C/002035
November 28, 2010
September 23, 2010
19
October 31, 2024
Company Information
Germany
Graf-Arco-Str. 3 D-89079 Ulm
ratiopharm GmbH
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Leflunomide is indicated for the treatment of adult patients with: - active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD); - active psoriatic arthritis. Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects. Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Leflunomide ratiopharm. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Leflunomide ratiopharm.